Sun Pharma Q2 Results: Systematix Maintains ‘Buy’ Rating After In-Line Performance
Sun Pharma Q2 Review: Systematix Maintains ‘Buy’ Post Inline Results — Check Target Price Sun Pharmaceutical Industries Ltd.’s revenues (Rs 144,783 million) grew by 8.9% YoY and 4.5% QoQ and were in line with our and consensus estimates. India business, Emerging Markets and Rest of World growth was strong (11%, 16%, 23% respectively), which was […]